miRview squamous

Home > miRview squamous: Healthcare Professional > miRview squamous

miRview® meso

miRview® mets² / mets

miRview® lung

The next generation of
cancer diagnostics is here

Introducing miRview® squamous

Rosetta Genomics is pleased to introduce
the next generation of cancer diagnostics: microRNA assays.

miRview® squamous is a cutting-edge molecular diagnostic test that uses microRNA to accurately differentiate squamous from nonsquamous NSCLC, helping you make informed decisions. Unlike current methods, miRview® squamous provides a differential diagnosis with

Fast, standardized, and objective classification
The highest level of accuracy demonstrated by 2 studies
- 100% sensitivity and specificity in a recent blinded, post-approval
  validation study¹
- In a study which determined the test's specification, the sensitivity and specificity were 97% and 91% respectively²
Simple interpretation
Routine sample preparation

Bishop JA, Benjamin H, Cholakh H, Chajat A, Clark DP, Westra WH. Accurate classification of non–small cell lung carcinoma using a novel microRNA-based approach. Clin Cancer Res. 2010;16(2):610-619.
Lebanony D, Benjamin H, Gilad S, et al. Diagnostic assay based on hsa-miR-205 expression distinguishes squamous from nonsquamous non-small-cell lung carcinoma. J Clin Oncol. 2009;27(12):2030-2037.


	For additional information, please download brochure Download